WuXi Biologics (Cayman) Inc. (WXIBF) Comparison with companies in other sectors?

WuXi Biologics (Cayman) Inc. has a share price of 4.07B. You can analyze WuXi Biologics (Cayman) Inc. (WXIBF) competitors across different market sectors through stock heatmaps.

What are WXIBF's NET and operating margins?

WuXi Biologics (Cayman) Inc. (WXIBF) operating margin is around 0.20, and net profit margin is approximately 0.15 as of the latest reports.

In what way does WXIBF's earnings per share (EPS) trend reflect its financial momentum?

WuXi Biologics (Cayman) Inc. (WXIBF) EPS is 0.11 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for WuXi Biologics (Cayman) Inc. is 36.36, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for WuXi Biologics (Cayman) Inc.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for WuXi Biologics (Cayman) Inc. like P/E which is 46.88, P/B which is 2.95, and PEG which is -0.30. Compare them with sector averages to evaluate if the stock is priced fairly.

WuXi Biologics (Cayman) Inc.

WXIBF•PNK

Healthcare

Biotechnology

$4.00

$0.20(5.26%)

Fundamental Analysis of WuXi Biologics (Cayman) Inc. (WXIBF)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$0.11

P/E Ratio

36.36

ROE

0.06%

Net Margin

0.15%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$16.28B

Shares OutstandingTotal number of shares issued

$4.07B

Book Value/ShareNet worth per share

$10.57

Revenue/ShareAnnual revenue per share

$3.98

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$0.11

Net MarginNet income as percentage of revenue

15.38%

Operating MarginOperating income as percentage of revenue

20.25%

ROEReturn on shareholders' equity

6.38%

ROAReturn on total assets

4.62%

ROCEReturn on capital employed

7.17%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-0.08

Cash/ShareCash and equivalents per share

$2.49

FCF YieldFree cash flow as percentage of market cap

-0.30%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for WXIBFFinancial Ratios Analysis details for WXIBF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for WXIBFSector Benchmarking details for WXIBF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for WuXi Biologics (Cayman) Inc. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of WuXi Biologics (Cayman) Inc.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account WuXi Biologics (Cayman) Inc.'s unique business strengths and challenges.

Key Financial Metrics for WuXi Biologics (Cayman) Inc.

For WuXi Biologics (Cayman) Inc., essential financial indicators include EPS 0.11, PE 36.36, and ROE 0.06. These key ratios reveal insights into WuXi Biologics (Cayman) Inc.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare WuXi Biologics (Cayman) Inc. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of WuXi Biologics (Cayman) Inc.

Metrics like Net Margin 15.38% and ROA 4.62% shed light on how well WuXi Biologics (Cayman) Inc. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether WuXi Biologics (Cayman) Inc. can sustain its operations and continue growing in the future.

Valuation and Market Position of WuXi Biologics (Cayman) Inc.

Using ratios such as P/B Ratio 2.95 and PEG Ratio -0.30, investors can assess whether WuXi Biologics (Cayman) Inc. is appropriately valued based on its financials and growth potential. These figures, combined with WuXi Biologics (Cayman) Inc.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for WuXi Biologics (Cayman) Inc.

Financial health indicators, such as Debt/Equity Ratio 0.12 and Cash Flow $-0.08, provide a snapshot of WuXi Biologics (Cayman) Inc.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like WuXi Biologics (Cayman) Inc., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for WuXi Biologics (Cayman) Inc.

Investing in WuXi Biologics (Cayman) Inc. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at WuXi Biologics (Cayman) Inc. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;